Epix buoyed by MRA (magnetic resonance angiography) contrast data
This article was originally published in Clinica
The second pivotal trial of Epix Medical's magnetic resonance angiography (MRA) contrast agent for detecting vascular disease has produced yet further evidence to support international marketing applications for the product.
You may also be interested in...
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.